These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35184067)

  • 1. Clinical and pathologic characteristics to select patients for focal therapy or partial gland ablation of nonmetastatic prostate cancer.
    Jaipuria J; Ahmed HU
    Curr Opin Urol; 2022 May; 32(3):224-230. PubMed ID: 35184067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer.
    Chesnut GT; Tin AL; Sivaraman A; Takeda T; Lee T; Fainberg J; Benfante N; Sjoberg DD; Vargas HA; Fine SW; Scardino PT; Eastham JA; Coleman JA; Touijer KA; Zelefsky MJ; Ehdaie B
    Urol Oncol; 2021 Aug; 39(8):495.e17-495.e24. PubMed ID: 33583697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal salvage low-dose-rate brachytherapy for recurrent prostate cancer based on magnetic resonance imaging/transrectal ultrasound fusion biopsy technique.
    Yamada Y; Okihara K; Masui K; Ueno A; Shiraishi T; Nakamura Y; Saito Y; Fujihara A; Hongo F; Yamada K; Ukimura O
    Int J Urol; 2020 Feb; 27(2):149-155. PubMed ID: 31721315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer.
    Eggener SE; Yousuf A; Watson S; Wang S; Oto A
    J Urol; 2016 Dec; 196(6):1670-1675. PubMed ID: 27449263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance after prostate focal therapy.
    Tay KJ; Amin MB; Ghai S; Jimenez RE; Kench JG; Klotz L; Montironi R; Muto S; Rastinehad AR; Turkbey B; Villers A; Polascik TJ
    World J Urol; 2019 Mar; 37(3):397-407. PubMed ID: 29948045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer.
    Orczyk C; Barratt D; Brew-Graves C; Peng Hu Y; Freeman A; McCartan N; Potyka I; Ramachandran N; Rodell R; Williams NR; Emberton M; Ahmed HU
    J Urol; 2021 Apr; 205(4):1090-1099. PubMed ID: 33315505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Candidates for Focal Therapy in Prostate Cancer in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Large Multicenter Cohort Study.
    von Hardenberg J; Borkowetz A; Siegel F; Kornienko K; Westhoff N; Jordan TB; Hoffmann M; Drerup M; Lieb V; Taymoorian K; Schostak M; Ganzer R; Höfner T; Cash H; Bruendl J;
    Eur Urol Focus; 2021 Sep; 7(5):1002-1010. PubMed ID: 33877047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer.
    Westin C; Chatterjee A; Ku E; Yousuf A; Wang S; Thomas S; Fan X; Eggener S; Karczmar G; Oto A
    AJR Am J Roentgenol; 2018 Sep; 211(3):595-604. PubMed ID: 29995499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation.
    von Hardenberg J; Westhoff N; Baumunk D; Hausmann D; Martini T; Marx A; Porubsky S; Schostak M; Michel MS; Ritter M
    Urol Oncol; 2018 Sep; 36(9):401.e1-401.e9. PubMed ID: 30093211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial.
    Ghai S; Perlis N; Lindner U; Hlasny E; Haider MA; Finelli A; Zlotta AR; Kulkarni GS; van der Kwast TH; McCluskey SA; Kucharczyk W; Trachtenberg J
    Eur Radiol; 2018 Oct; 28(10):4281-4287. PubMed ID: 29696431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning.
    Sidelsky S; Setia S; Vourganti S
    Curr Urol Rep; 2017 Oct; 18(12):93. PubMed ID: 29046984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focal Ablation of Early-Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome.
    Edison E; Tariq Shah T; Ahmed HU
    Urol Clin North Am; 2017 Nov; 44(4):575-585. PubMed ID: 29107274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted prostate biopsy and MR-guided therapy for prostate cancer.
    Woodrum DA; Kawashima A; Gorny KR; Mynderse LA
    Abdom Radiol (NY); 2016 May; 41(5):877-88. PubMed ID: 26907717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study.
    Ehdaie B; Tempany CM; Holland F; Sjoberg DD; Kibel AS; Trinh QD; Durack JC; Akin O; Vickers AJ; Scardino PT; Sperling D; Wong JYC; Yuh B; Woodrum DA; Mynderse LA; Raman SS; Pantuck AJ; Schiffman MH; McClure TD; Sonn GA; Ghanouni P
    Lancet Oncol; 2022 Jul; 23(7):910-918. PubMed ID: 35714666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1.
    Apfelbeck M; Clevert DA; Ricke J; Stief C; Schlenker B
    Clin Hemorheol Microcirc; 2018; 69(1-2):93-100. PubMed ID: 29660918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to select the right patients for focal therapy of prostate cancer?
    Passoni NM; Polascik TJ
    Curr Opin Urol; 2014 May; 24(3):203-8. PubMed ID: 24625428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes.
    Qaoud Y; Herrera-Caceres JO; Bass R; Berjaoui MB; Tiwari R; Kenk M; Lajkosz K; Finelli A; Perlis N; Klotz L; Fleshner N
    Urol Oncol; 2022 Jul; 40(7):343.e1-343.e6. PubMed ID: 35537905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extra-target low-risk prostate cancer: implications for focal high-intensity focused ultrasound of clinically significant prostate cancer.
    Annoot A; Olivier J; Valtille P; Deken V; Leroy X; Puech P; Villers A
    World J Urol; 2019 Feb; 37(2):261-268. PubMed ID: 30116963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
    Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
    Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.